Effects of growth factors and receptor blockade on gastrointestinal cancer.
The advent of recombinant peptide technology offers the potential to use one or several peptides to treat a variety of gastrointestinal conditions. However, although cell culture and animal models have shown proof of concept, we are still at a relatively early stage in translating their use to standard clinical practice. Similarly, peptide and non-peptide antagonists of growth factor receptors show great potential as novel antichemotherapy agents. However, their actual place in clinical practice has yet to be established.
Playford
R J
RJ
Gastroenterology Section, Division of Medicine, Imperial College London, Hammersmith Hospital, London, UK. r.playford@imperial.ac.uk
Wassan
H
H
Ghosh
S
S
D066246:ErbB Receptors / Q000378:metabolism; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006131:Growth Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006133:Growth Substances / Q000009:adverse effects / Q000819:agonists*; D006801:Humans; D010455:Peptides / Q000378:metabolism / Q000627:therapeutic use; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors*; D011995:Recombination, Genetic; D012307:Risk Factors; D015398:Signal Transduction / Q000502:physiology
D006131:Growth Inhibitors; D006133:Growth Substances; D010455:Peptides; D017978:Receptors, Growth Factor; D066246:ErbB Receptors